Sfe Investment Counsel Crispr Therapeutics Ag Transaction History
Sfe Investment Counsel
- $479 Million
- Q1 2025
A detailed history of Sfe Investment Counsel transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Sfe Investment Counsel holds 6,507 shares of CRSP stock, worth $240,433. This represents 0.05% of its overall portfolio holdings.
Number of Shares
6,507
Previous 6,152
5.77%
Holding current value
$240,433
Previous $242,000
8.68%
% of portfolio
0.05%
Previous 0.05%
Shares
6 transactions
Others Institutions Holding CRSP
# of Institutions
479Shares Held
64.2MCall Options Held
2.15MPut Options Held
1.92M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl10.2MShares$376 Million3.73% of portfolio
-
Capital International Investors Los Angeles, CA6.07MShares$224 Million0.04% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.8MShares$140 Million0.09% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$103 Million0.0% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.2.54MShares$93.8 Million0.06% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $2.88B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....